Dulaglutide trulicity patent expiry 2027 2028?

Short answer: there isn’t a single “Dulaglutide patent expiry” date. Trulicity (dulaglutide) is protected by multiple patent families plus regulatory exclusivities, and expiry varies by jurisdiction and by patent type (composition of matter, formulation, methods of use, devices, etc.).

What that usually means in practice
- In the US, there is 12-year data exclusivity under BPCIA for biologics, which generally blocks approval of a biosimilar based on the same data until around 2026. Patent protection for the molecule and associated formulations can extend beyond that, often into the late 2020s or even longer, depending on the patent family.
- In the EU and other regions, patent protection plus any supplementary protections (like SPCs) can push protection into the late 2020s or into the 2030s, again depending on the specific patents.
- Because there are multiple patents (molecule/composition, formulations, manufacturing processes, uses, and related devices), some may expire earlier (2027–2028 in some jurisdictions) while others could extend later.

How to check current expiry for your needs
- US:
- FDA Purple Book (biologics) for patents and exclusivity related to dulaglutide/trulicity.
- Google Patents or USPTO Patent Center for the dulaglutide patent families and their expiration dates.
- EU and other regions:
- Espacenet (EPO) or national patent offices for national patent expiry dates.
- Check for any SPCs that extend protection in those countries.
- If you want, I can look up the latest status for a specific jurisdiction (e.g., US, EU) and summarize the relevant patent expiry and exclusivity dates. Tell me which country/region you care about.

Would you like me to pull the latest patent-exclusivity status for the US or a particular region?